Robert Lutz
Company: Iksuda Therapeutics
Job title: Chief Scientific Officer
Seminars:
Chairperson’s Opening Remarks 9:25 am
day: Day Two
Panel Discussion – Thinking Strategically About What Targets You Select 3:30 pm
Understanding where your target choice and ADC fits into the ADC and wider oncology landscape? How do you differentiate yourself through using improved linker-payload technologies on previously validated targets? Balancing risk in your pipeline through your target choice Novel targets or previously validated targets? Discussing the role of future HER2 ADCsRead more
day: Day One
The Vital Triad of ADC Design: Target, Indication & Payload 9:30 am
Reviewing how the selection of an ADC target requires consideration of the potential clinical indications and the mechanistic properties of available linker payloads Assessing how the availability of novel differentiated linker-payloads provides an opportunity to calibrate potential clinical success against validated clinical benchmarks Presenting case study examples to demonstrate integration of target selection, clinical indication…Read more
day: Day One